Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$880.83 USD

880.83
1,130,837

-4.72 (-0.53%)

Updated Oct 4, 2024 02:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Eli Lilly (LLY) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $332.76 in the latest trading session, marking a +0.41% move from the prior day.

The Zacks Analyst Blog Highlights Microsoft, Alphabet, Eli Lilly, Visa and Morgan Stanley

by Zacks Equity Research

Microsoft, Alphabet, Eli Lilly, Visa and Morgan Stanley are included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Microsoft, Alphabet & Eli Lilly

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Alphabet Inc. (GOOGL) and Eli Lilly and Company (LLY).

J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector

by Zacks Equity Research

J&J's (JNJ) Pharma segment is expected to have performed above the market. In the MedTech segment, sales in the second half are expected to have been better than the first.

Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Rigel (RIGL) to Not Pursue the WAIHA Program, Cut Jobs

by Zacks Equity Research

Rigel (RIGL) decides to back out from the label expansion of fostamatinib for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA) following the FDA???s review.

Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $323.89 in the latest trading session, marking a -0.85% move from the prior day.

Annovis (ANVS) Gains on FDA Authorization for AD Study

by Zacks Equity Research

Annovis (ANVS) shares jump following the FDA's authorization to proceed with the phase II/III clinical study of lead candidate buntanetap in moderate Alzheimer's Disease (AD).

Lilly's (LLY) Diabetes Drug Gets FDA Fast Track Tag for Obesity

by Zacks Equity Research

Eli Lilly (LLY) receives a fast-track designation from the FDA for tirzepatide to treat obesity in adult patients. The company will begin rolling NDA submission later this year.

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed the most recent trading day at $321.55, moving -0.56% from the previous trading session.

Will Acquisitions Help Novo Nordisk (NVO) Combat Stiff Rivalry?

by Zacks Equity Research

Novo Nordisk (NVO) expects new acquisitions to diversify its portfolio of marketed drugs and help combat the stiff competition in the diabetes market.

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PJP

Ekta Bagri headshot

LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data

by Ekta Bagri

The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.

Biogen's (BIIB) Lecanemab Meets Goal in Alzheimer's Study

by Zacks Equity Research

Biogen (BIIB) and Eisai's Clarity AD study showed that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of clinical decline on the CDR-SB scale by 27% compared to placebo.

AZN vs. LLY: Which Stock Is the Better Value Option?

by Zacks Equity Research

AZN vs. LLY: Which Stock Is the Better Value Option?

Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed the most recent trading day at $307.50, moving -1.27% from the previous trading session.

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod to AZN & RHHBY Drugs, FDA Updates for LLY & MRK

by Kinjel Shah

Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.

Strength Seen in Lilly (LLY): Can Its 4.9% Jump Turn into More Strength?

by Zacks Equity Research

Lilly (LLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Eli Lilly (LLY) Gets FDA Nod for RET Inhibitor in Solid Tumors

by Zacks Equity Research

The FDA grants approval to Lilly's (LLY) Retevmo in advanced or metastatic solid tumors with a RET gene fusion. It converts the drug's accelerated approval in NSCLC indication to full approval.

AstraZeneca (AZN) Gets EU Nod for Evusheld to Treat COVID

by Zacks Equity Research

Following the label expansion approval in the European Union, Evusheld is currently the only long-acting antibody combination available for both prevention and treatment of COVID-19.

Eli Lilly (LLY) Stock Moves -1.1%: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $301.73 in the latest trading session, marking a -1.1% move from the prior day.

Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $309.61 in the latest trading session, marking a +1.02% move from the prior day.

Syros (SYRS) Up on FDA's Orphan Tag for Pancreatic Cancer Drug

by Zacks Equity Research

Syros Pharmaceuticals (SYRS) receives Orphan Drug designation from the FDA for its pipeline candidate AY-5609 being developed for treating metastatic pancreatic cancer. Stock up.

The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo, International Business Machines, Booking Holdings, Northrop Grumman Corporation and Illinois Tool Works

by Zacks Equity Research

Eli Lilly, PepsiCo, International Business Machines, Booking Holdings, Northrop Grumman Corporation and Illinois Tool Works are included in this Analyst Blog.